Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

120P Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Characterization of the circulating immune response in the AVETUXIRI phase II trial

Title: 120P Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Characterization of the circulating immune response in the AVETUXIRI phase II trial
Authors: Benidovskaya, Elena; Huyghe, Nicolas; Carrasco, Javier; De Cuyper, Astrid; Sinapi, Isabelle; Verstraelen, Eléonore; Goffette, Pierre; Ghaye, Benoît; Papier, M.; Van Maanen, Aline; Castella, Marie-Laure; Galon, Jérôme; Van den Eynde, Marc; the ESMO Gastrointestinal Cancers Congress 2024
Contributors: UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie; UCL - (SLuc) Service d'oncologie médicale
Source: Annals of Oncology, Vol. 35, no.Suppl 1, p. S56 (2024)
Publisher Information: Elsevier
Publication Year: 2024
Collection: DIAL@USL-B (Université Saint-Louis, Bruxelles)
Description: Background : Clinical efficacy and safety of AVE, CET and IRI have previously been reported for the treatment of refractory MSS mCRC. Here, we aim to characterize the systemic immune response and investigate its potential role in response to immunotherapy. [.]
Document Type: conference object
Language: English
Relation: boreal:299292; http://hdl.handle.net/2078.1/299292
DOI: 10.1016/j.annonc.2024.05.131
Availability: http://hdl.handle.net/2078.1/299292; https://doi.org/10.1016/j.annonc.2024.05.131
Rights: info:eu-repo/semantics/openAccess
Accession Number: edsbas.36C49EE
Database: BASE